Kebilidi™ (Eladocagene Exuparvovec-Tneq) – Commercial Medical Benefit Drug Policyopen_in_new

UnitedHealthcare covers Kebilidi (eladocagene exuparvovec‑tneq) for AADC deficiency but excludes patients who previously received Kebilidi or other gene therapy and is limited to a single lifetime treatment, subject to FDA dosing and member/state plan terms. Key requirements include genetically confirmed biallelic DDC mutations with decreased plasma AADC activity, skull maturity on neuroimaging, persistent symptoms despite standard therapy and inability to ambulate independently, anti‑AAV2 titer ≤1:1200 (ELISA OD ≤1), prescription by a neurologist/neurosurgeon, and submission of supporting medical records (authorization valid ≤60 days).

"Coverage is contingent on dosing being in accordance with the United States Food and Drug Administration approved labeling"

Sign up to see full coverage criteria, indications, and limitations.